Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Center for Kidney Disease, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China Background: Ferroptosis of kidney tubular epithelial cells contributes to the pathogenesis of ...

Introduction: Artificial light at night (LAN) is associated with metabolic diseases, but its precise relationship is still not fully understood. This study explores the association between LAN and ...